FEATURE
just its first year of use, use of the care path
led to 93 percent of patients receiving the
recommended front-line treatment (vs. 71%
in the comparison group) and significantly
lowered the number of patients who received
a non-recommended drug (9% vs. 39% in the
comparison group). The researchers calculated that, overall, charges for chemotherapy
decreased by nearly half.2 “Multiple, different standards of care exist for non-small cell
lung cancer, and no one standard of care has
proven to be better for survival,” the authors
wrote, however, the regimen selected for
this study was shown to demonstrate the
“best value for care, meaning lower costs and
lower rates of adverse effects, while achieving the same survival rates and comparable
quality of life.”
Shoving Into a One-Size-Fits-All
Model?
“Our use of care paths is couched in certain
factors,” Dr. Bolwell noted. “Number one: Any
time a patient is eligible for a clinical research
trial, that is the preferred approach. Number
two: There are defined ways to incorporate new
drugs, if a new drug has been shown to be better
than the standard of care.”
While Dr. Bolwell believes that care paths
have played a big part in Cleveland Clinic’s
strategy, he also acknowledged that their use
can be too rigid – a potential drawback that critics of care paths have been quick to point out.
CMYK
EN
DE
When multiple myeloma relapses
AV NEW
OR †
ST
U
RESPOND
with the superior power of the KYPROLIS doublet (Kd)
1
*
plus dexamethasone (Kd) provided double the median PFS vs bortezomib
plus dexamethasone ( Vd) in patients with relapsed multiple myeloma.1
* KYPROLIS
NEW HEAD-TO-HEAD DATA VS BORTEZOMIB DOUBLET (Vd) SHOWED
Median PFS1
2x
INCREASED
Complete response or better (≥ CR)1
• 18.7 months for Kd vs 9.4 months for Vd,
one-sided P < 0.00011
• 13% for Kd vs 6% for Vd1
See more results at Kyprolis-HCP.com
ENDEAVOR†: A phase 3, randomized, open-label, multicenter superiority study compared KYPROLIS plus dexamethasone (Kd) to bortezomib plus dexamethasone (V